Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

Core Viewpoint - Krystal Biotech, Inc. will report its fourth quarter and full year 2025 financial results on February 17, 2026, before U.S. markets open, and will host a conference call and webcast to discuss these results and provide a business update [1]. Company Overview - Krystal Biotech, Inc. is a fully integrated, commercial-stage global biotechnology company focused on discovering, developing, and commercializing genetic medicines for diseases with high unmet medical needs [3]. - The company's first commercial product, VYJUVEK, is the first-ever redosable gene therapy and the first genetic medicine approved in the U.S., Europe, and Japan for treating dystrophic epidermolysis bullosa [3]. - Krystal Biotech is advancing a robust pipeline of investigational genetic medicines and is headquartered in Pittsburgh, Pennsylvania [3].